Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Hayeon Noh, Su Young Jung, Jae-Yong Kwak, MD PhD, Sung-Hyun Kim, Suk Joong Oh, Dae Young Zang, Hye Lin Park, Dae Jin Jo, Jae Soo Shin, Young Rok Do, Dong-Wook Kim, MD PhD, Jangik I Lee

Blood (2016) 128 (22): 3086.

https://doi.org/10.1182/blood.V128.22.3086.3086

Published: 2016

Journal Articles

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Jee Hyun Kong, Dr, Young-Woo Jeon, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Suk Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5535.

https://doi.org/10.1182/blood.V124.21.5535.5535

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 1499.

https://doi.org/10.1182/blood.V122.21.1499.1499

Published: 2013

Journal Articles

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

Blood (2012) 120 (21): 695.

https://doi.org/10.1182/blood.V120.21.695.695

Published: 2012

Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Blood (2012) 120 (21): 3775.

https://doi.org/10.1182/blood.V120.21.3775.3775

Published: 2012

Journal Articles

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Hyun-Gyung Goh, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk-Joong Oh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Sung-Eun Lee, Dongho Kim, Ji-Young Byeun, Richard C. Woodman, Tomasz Szczudlo, Hee Jung Kim, Dong-Wook Kim

Blood (2011) 118 (21): 2765.

https://doi.org/10.1182/blood.V118.21.2765.2765

Published: 2011

Journal Articles

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Blood (2010) 116 (21): 2272.

https://doi.org/10.1182/blood.V116.21.2272.2272

Published: 2010

Journal Articles

Intensified 1st Cycle Rituximab (R) Plus 8 th Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20 + Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.

Jin Seok Kim, Won Seog Kim, Seok Jin Kim, MD, PhD, Hyeon Seok Eom, Deok-Hwan Yang, Yang Soo Kim, Hyo Jung Kim, Min Kyoung Kim, Suk-Joong Oh, Sung-Soo Yoon, Hun-Mo Ryoo, MD, PhD, Jae-Yong Kwak, Jae Hoon Lee, MD, PhD, Chul Won Choi, Hye Jin Kang, Yeung-Chul Mun, yun Deok Kim, Cheolwon Suh, MD

Blood (2010) 116 (21): 1786.

https://doi.org/10.1182/blood.V116.21.1786.1786

Published: 2010

Journal Articles

The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotying in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.

Blood (2009) 114 (22): 4902.

https://doi.org/10.1182/blood.V114.22.4902.4902

Published: 2009

Journal Articles

Velcade ® , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial

HyeonSeok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Kihyun Kim, Hyo-Jung Kim, HoYoung Kim, Jong-Youl Jin, Young-Rok Do, Suk-Joong Oh, Cheolwon Suh, Chu-Myong Seong, Chul Soo Kim, Dong Soon Lee, Jae Hoon Lee

Blood (2008) 112 (11): 2785.

https://doi.org/10.1182/blood.V112.11.2785.2785

Published: 2008

Journal Articles

Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML

Blood (2008) 112 (11): 3221.

https://doi.org/10.1182/blood.V112.11.3221.3221

Published: 2008

Journal Articles

Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.

Blood (2007) 110 (11): 1361.

https://doi.org/10.1182/blood.V110.11.1361.1361

Published: 2007

Journal Articles

Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.

Byeong-Bae Park, MD, Jong Gwang Kim, MD,PhD, HyeonSeok Eom, MD,PhD, Hyo Jin Kim, MD,PhD, Hyuck Chan Kwon, MD,PhD, Sung Yong Oh, MD, Jung Hun Kang, MD, Suk Joong Oh, MD,PhD, Ho-Jin Shin, MD,PhD, Cheolwon Suh, MD,PhD, Jung Han Kim, MD, Ho Young Kim, MD, Sang Cheol Lee, MD, Kihyun Kim, MD,PhD, Chul W. Jung, MD,PhD, Won Seog Kim, MD,PhD

Blood (2006) 108 (11): 4670.

https://doi.org/10.1182/blood.V108.11.4670.4670

Published: 2006

NARROW

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Intensified 1st Cycle Rituximab (R) Plus 8 th Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20 + Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.

The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotying in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.

Velcade ® , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial

Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML

Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.

Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only